Challenging the equipotency calculation for transdermal buprenorphine: four case studies
Authors:
- 18 December 2007
- journal article
- case report
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 62 (1) , 152-156
Abstract
Opioids produce analgesia via different pain pathways. The aim of these case studies was to address the issue of opioid rotation or switching, raising the important issue of conversion ratios between different compounds and routes of administration. We present two cases of neuropathic pain and two cases of nociceptive pain with a significant neuropathic component, which were successfully treated with transdermal buprenorphine after the failure of other opioids. In each case, effective pain relief was produced by a lower dose than the proposed equipotency ratio of 1:75 would indicate, suggesting that a ratio of 1:110 to 1:115 may be more appropriate.Keywords
This publication has 20 references indexed in Scilit:
- Opioid switching: A systematic and critical reviewCancer Treatment Reviews, 2006
- Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: Results of a retrospective cohort studyClinical Therapeutics, 2005
- The Orvinols and Related Opioids - High Affinity Ligands with Diverse Efficacy ProfilesCurrent Pharmaceutical Design, 2004
- The use of long-acting opioids in chronic pain managementNursing Clinics of North America, 2003
- Equianalgesic Dose Ratios for OpioidsJournal of Pain and Symptom Management, 2001
- Management of cancer painThe Lancet, 1999
- Transdermal fentanyl versussustained-release oral morphine in cancer pain: Preference, efficacy, and quality of lifeJournal of Pain and Symptom Management, 1997
- Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic painThe Lancet, 1997
- Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective studyPain, 1995
- Treatment Principles for the Use of Opioids in Pain of Nonmalignant OriginDrugs, 1991